Cargando…

Cost-effectiveness of new MDR-TB regimens: study protocol for the TB-PRACTECAL economic evaluation substudy

INTRODUCTION: Current treatment regimens for multidrug-resistant tuberculosis (MDR-TB) are long, poorly tolerated and have poor outcomes. Furthermore, the costs of treating MDR-TB are much greater than those for treating drug-susceptible TB, both for health service and patient-incurred costs. Urgent...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sweeney, Sedona, Gomez, Gabriela, Kitson, Nichola, Sinha, Animesh, Yatskevich, Natalia, Staples, Suzanne, Moodliar, Ronelle, Motlhako, Sharon, Maloma, Matshepo, Rassool, Mohammed, Ngubane, Nosipho, Ndlovu, Ella, Nyang'wa, Bern-Thomas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2020
Materias:	Health Economics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7549492/ https://www.ncbi.nlm.nih.gov/pubmed/33039989 http://dx.doi.org/10.1136/bmjopen-2019-036599

Ejemplares similares

Capturing patient-reported and quality of life outcomes with use of shorter regimens for drug-resistant tuberculosis: mixed-methods substudy protocol, TB PRACTECAL-PRO
por: Stringer, Beverley, et al.
Publicado: (2021)

Population pharmacokinetics and pharmacodynamics of investigational regimens’ drugs in the TB-PRACTECAL clinical trial (the PRACTECAL-PKPD study): a prospective nested study protocol in a randomised controlled trial
por: Nyang'wa, Bern-Thomas, et al.
Publicado: (2021)

TB-PRACTECAL: study protocol for a randomised, controlled, open-label, phase II–III trial to evaluate the safety and efficacy of regimens containing bedaquiline and pretomanid for the treatment of adult patients with pulmonary multidrug-resistant tuberculosis
por: Berry, Catherine, et al.
Publicado: (2022)

Association of BMI Category Change with TB Treatment Mortality in HIV-Positive Smear-Negative and Extrapulmonary TB Patients in Myanmar and Zimbabwe
por: Benova, Lenka, et al.
Publicado: (2012)

TB research requires strong protections, innovation, and increased funding in response to COVID-19
por: Nyang’wa, B. T., et al.
Publicado: (2021)

‘Z(S)-MDR-TB' versus ‘Z(R)-MDR-TB': improving treatment of MDR-TB by identifying pyrazinamide susceptibility
por: Zhang, Ying, et al.
Publicado: (2012)

Cost-effectiveness of short, oral treatment regimens for rifampicin resistant tuberculosis
por: Sweeney, Sedona, et al.
Publicado: (2022)

MDR TB Transmission, Singapore
por: Chee, Cynthia B.E., et al.
Publicado: (2013)

Multidrug-Resistant TB (MDR-TB) and Extensively Drug-Resistant TB (XDR-TB) Among Children: Where We Stand Now
por: Chowdhury, Kona, et al.
Publicado: (2023)

Bedaquiline for multidrug-resistant TB in paediatric patients
por: Moodliar, R., et al.
Publicado: (2021)

Heightened Vulnerability to MDR-TB Epidemics after Controlling Drug-Susceptible TB
por: Bishai, Jason D., et al.
Publicado: (2010)

The incidence of TB and MDR-TB in pediatrics and therapeutic options: a systematic review
por: Harichander, Sheetal, et al.
Publicado: (2022)

Six-Month Response to Delamanid Treatment in MDR TB Patients
por: Hewison, Cathy, et al.
Publicado: (2017)

SEVERITY OF TB CLASSIFIED BY MODIFIED BANDIM TB SCORING ASSOCIATES WITH THE SPECIFIC SEQUENCE OF ESXA GENES IN MDR-TB PATIENTS
por: Dewi, Desak Nyoman Surya Suameitria, et al.
Publicado: (2020)

Community-based MDR-TB care project improves treatment initiation in patients diagnosed with MDR-TB in Myanmar
por: Wai, Pyae Phyo, et al.
Publicado: (2018)

Correction: The incidence of TB and MDR-TB in pediatrics and therapeutic options: a systematic review
por: Harichander, Sheetal, et al.
Publicado: (2022)

Costs of TB services in India
por: Chatterjee, S., et al.
Publicado: (2021)

Early outcomes in MDR-TB and XDR-TB patients treated with delamanid under compassionate use
por: Hafkin, Jeffrey, et al.
Publicado: (2017)

The endTB observational study protocol: treatment of MDR-TB with bedaquiline or delamanid containing regimens
por: Khan, Uzma, et al.
Publicado: (2019)

Molecular characterization of multidrug-resistant Mycobacterium tuberculosis (MDR-TB) isolates identifies local transmission of infection in Kuwait, a country with a low incidence of TB and MDR-TB
por: Al-Mutairi, Noura M., et al.
Publicado: (2019)

Management of MDR-TB: Review of Iran's Experience
por: Masjedi, Mohammad Reza, et al.
Publicado: (2013)

MDR-TB in Pakistan: Challenges, efforts, and recommendations
por: Khan, Mahad Ahmed, et al.
Publicado: (2022)

Issues in design and interpretation of MDR-TB clinical trials: report of the first Global MDR-TB Clinical Trials Landscape Meeting
por: Mitnick, Carole D, et al.
Publicado: (2015)

Correction to: Molecular characterization of multidrug-resistant Mycobacterium tuberculosis (MDR-TB) isolates identifies local transmission of infection in Kuwait, a country with a low incidence of TB and MDR-TB
por: Al-Mutairi, Noura M., et al.
Publicado: (2020)

TB Anywhere is TB Everywhere
por: Wortham, Jonathan M.
Publicado: (2018)

TB or not TB! That’s the question
por: Nugud, Ahmed, et al.
Publicado: (2019)

Prospective evaluation of simply modified MODS assay: an effective tool for TB diagnosis and detection of MDR-TB
por: Chaiyasirinroje, Boonchai, et al.
Publicado: (2012)

Prevalence and Factors Associated with Multidrug-Resistant Tuberculosis (MDR-TB) among Presumptive MDR-TB Patients in Tigray Region, Northern Ethiopia
por: Mehari, Kibriti, et al.
Publicado: (2019)

Performance of spirometry assessment at TB diagnosis
por: Rachow, A., et al.
Publicado: (2023)

First Outcome of MDR-TB among Co-Infected HIV/TB Patients from South-West Iran
por: Motamedifar, Mohammad, et al.
Publicado: (2015)

Why has MDR-TB prevalence increased in Iran?
por: Heidary, Mohsen, et al.
Publicado: (2016)

Predictors of Multidrug-Resistant Tuberculosis (MDR-TB) in Sudan
por: Ali, Monadil H., et al.
Publicado: (2019)

Fluoroquinolone preventive therapy for children exposed to MDR-TB
por: Gureva, T., et al.
Publicado: (2022)

Analysis of multi drug resistant tuberculosis (MDR-TB) financial protection policy: MDR-TB health insurance schemes, in Chhattisgarh state, India
por: Kundu, Debashish, et al.
Publicado: (2018)

Collaborative public–private initiatives targeting multidrug-resistant tuberculosis (MDR-TB) supported by the Lilly MDR-TB Partnership: experiences in 2012–2016
por: Shelby, Peter W, et al.
Publicado: (2017)

759. Molecular Characterization and Epidemiology of Multidrug-Resistant Mycobacterium tuberculosis (MDR-TB) and Identification of Possible Cases of Local Transmission of MDR-TB in Kuwait
por: Mokaddas, Eiman, et al.
Publicado: (2018)

Measuring Quality Gaps in TB Screening in South Africa Using Standardised Patient Analysis
por: Christian, Carmen S., et al.
Publicado: (2018)

Patterns of Treatment Interruption among Patients with Multidrug-Resistant TB (MDR TB) and Association with Interim and Final Treatment Outcomes
por: Podewils, Laura Jean, et al.
Publicado: (2013)

Risk Factors for Poor Treatment Outcomes in Patients with MDR-TB and XDR-TB in China: Retrospective Multi-Center Investigation
por: Tang, Shenjie, et al.
Publicado: (2013)

Striking the Right Balance Determines TB or Not TB
por: BoseDasgupta, Somdeb, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_6pvad2ngkro7c3vt81ouuqoplt